NEWARK, Calif., Dec. 10, 2020 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage
biopharmaceutical company, today announced that it has commenced an
underwritten public offering of $100,000,000 of shares of its common stock. All
of the shares of common stock are being offered by Protagonist. In
connection with this offering, Protagonist expects to grant the
underwriters a 30-day option to purchase up to an additional 15% of
the number of shares of its common stock offered in the public
offering.
J.P. Morgan Securities LLC, SVB Leerink LLC, Piper Sandler
& Co. and BMO Capital Markets Corp. are acting as joint
book-running managers for the offering. The offering is subject to
market conditions and there can be no assurance as to whether or
when the offering may be completed or the actual size or terms of
the offering.
A shelf registration statement relating to the offered shares of
common stock was filed with the Securities and Exchange
Commission (SEC) on December 10,
2020. A preliminary prospectus supplement and accompanying
prospectus relating to the offering will be filed with
the SEC and will be available on the SEC's website,
located at www.sec.gov. Prospective investors should read the
preliminary prospectus supplement, when available, and the
accompanying prospectus and other documents Protagonist has filed
with the SEC for more complete information about
Protagonist and the offering. Copies of the prospectus supplement
and the accompanying prospectus related to the offering may be
obtained, when available, from J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, by telephone
at (866) 803-9204 or by email at
prospectus-eq_fi@jpmchase.com; from SVB Leerink LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, by telephone at
(800) 808-7525, ext. 6132 or by email at syndicate@svbleerink.com;
from Piper Sandler & Co.,
Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, by
telephone at (800) 747-3924 or by email at prospectus@psc.com; or
from BMO Capital Markets Corp., Attn: Equity Syndicate Department,
3 Times Square, 25th Floor, New York,
NY 10036, tel: (800) 414-3627, email:
bmoprospectus@bmo.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding Protagonist's expectations regarding the
completion, timing and size of the proposed public offering. In
some cases, you can identify these statements by forward-looking
words such as "expect," "may," "will," or the negative or
plural of these words or similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances). These forward-looking statements are based on
Protagonist's expectations and assumptions as of the date of this
press release. Each of these forward-looking statements involves
risks and uncertainties. Actual results may differ materially from
these forward-looking statements. These risks and uncertainties
include, without limitation, risks and uncertainties related to
market conditions and satisfaction of customary closing conditions
related to the proposed public offering. There can be no assurance
that Protagonist will be able to complete the proposed public
offering on the anticipated terms, or at all. Additional
information concerning these and other risks can be found in
Protagonist's periodic filings with the U.S. Securities and
Exchange Commission, including under the heading "Risk Factors"
contained therein, as well as the risks identified in the
registration statement and the preliminary prospectus supplement
relating to the offering. Any forward-looking statements that
Protagonist makes in this press release speak only as of the date
of this press release. Except as required by law, Protagonist
assumes no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise,
after the date of this press release.
View original
content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-inc-announces-proposed-public-offering-of-common-stock-301190335.html
SOURCE Protagonist Therapeutics, Inc.